February 16, 2010 — The quadrivalent vaccine against human papillomavirus (HPV) types 6, 11, 16, and 18 (Gardasil, Merck & Co) results in statistically significant reductions of HPV-associated genital diseases, such as warts and cervical dysplasia, in young women who receive it, according to the final analysis of 2 randomized placebo-controlled efficacy trials.
Read more...
Source:
http://cme.medscape.com
No comments:
Post a Comment